Potential role of Rho-associated protein kinase inhibitors for glaucoma treatment

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 2, 2012, Pages 89-98

  Colligris, Basilio ^a   Crooke, Almudena ^a   Huete, Fernando ^a   Pintor, Jesus ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Glaucoma; Heteroaromatic compounds; Inhibitors; Intraocular pressure; Rho kinase; Trabecular meshwork

Indexed keywords

1 (4 FLUORO 5 ISOQUINOLINESULFONYL) 2 METHYL 1,4 HOMOPIPERAZINE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIGLAUCOMA AGENT; AR 12286; AROMATIC COMPOUND; ATS 907; BEFUNOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; DE 104; FASUDIL; INS 115644; INS 117548; ISOQUINOLINE DERIVATIVE; K 115; LATANOPROST; LATRUNCULIN A; LATRUNCULIN B; N (1H PYRROLO[2,3 B]PYRIDIN 4 YL) 4 (1 AMINOETHYL)BENZAMIDE; NIPRADILOL; PROSTAGLANDIN DERIVATIVE; RHO KINASE; RHO KINASE INHIBITOR; SNJ 1656; TIMOLOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNOPROSTONE ISOPROPYL ESTER; Y 39983;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; EYE BURNING; EYE IRRITATION; GLAUCOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; OPEN ANGLE GLAUCOMA; OPTIC NERVE; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRABECULAR MESHWORK; TREATMENT OUTCOME;

EID: 84861780632     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412800604554     Document Type: Article

References (49)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90:262-7.
2. Lee AJ, Goldberg I. Emerging drugs for ocular hypertension Expert Opin Emerg Drugs 2011; 16:137-61.
3. Byth KF, Cooper N, Culshaw JD, Heaton DW, Oakes SE, Minshull CA, et al. Imidazo[1,2-b]pyridazines: A potent and selective class of cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett 2004; 14:2249-52.
4. Riento K, Ridley AJ. Rocks: Multifunctional kinases in cell behavior. Nat Rev Mol Cell Biol 2003; 4:446-56.
5. Ray P, Wright J, Adam J, Boucharens S, Black D, Brown AR, et al. Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors. Bioorg Med Chem Lett 2011; 21:1084-8.
6. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol 2008; 126:309-15.
7. Koga T, Awai M, Tsutsui J, Yue BY, Tanihara H. Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells. Exp Eye Res 2006; 82:362-70.
8. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y27632. Invest Ophthalmol Vis Sci 2001; 42:1029-37.
9. Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: A patent review 2007 - 2011. Expert Opin Ther Pat 2012; 22:79-88.
10. deLong MA, Sturdivant JM, Royalty SM, Heintzelman GR, Yingling JD, Laethem CL, et al. Discovery and in vitro SAR of AR- 12286, a potent kinase inhibitor for the treatment of glaucoma. Proceedings of 2009 Annual Meeting of the Association for Research in Vision and Opthalmology, Ft. Lauderdale, USA, 2009.
11. deLong, M. A., Sturdivant J. M., Heintzelman, G. R., Royalty, S. M. 6-Aminoisoquinoline compounds. US20070173530 (2007), US20107671205 (2010), US20100137364 (2010), US20110319390 (2011), US20118034943 (2011) & US20110183965 (2011).
12. deLong, M. A., Sturdivant, J. M., Heintzelman, G. R., Royalty, S. M. 6-And 7-Amino isoquinoline compounds and methods for making and using the same. US20100144713 (2010).
13. RhoKing glaucoma. BioCentury, the Bernstein Report on BioBusiness. Available at: http://www.biocentury.com (Accessed on: April 04, 2012).
14. Delorme-Axford E, Coyne CB. The actin cytoskeleton as a barrier to virus infection of polarized epithelial cells. Viruses 2011; 3:2462-77.
15. Terry S, Nie M, Matter K, Balda MS. Rho signaling and tight junction functions. Physiology (Bethesda) 2010; 25:16-26.
16. Ethier CR, Read AT, Chan DW. Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes. Invest Ophthalmol Vis Sci 2006; 47:1991-8.
17. Lampe, J.W., Watson, P.S., Slade, D.J., Peterson, W.M., Crean, C.S., Vittitow, J.L., DeCamp, J.B., Pelz, N.F. Cytoskeletal active Rho kinase inhibitor compounds, composition and use. US20118071779 (2011).
18. Lampe, J.W., Plourde, R., She, J., Vittitow, J.L., Watson, P.S., Crimmins, M.T., Slade, D.J. Cytoskeletal active compounds, compositions and use. US20087320974 (2008), US20107666861 (2010) & US20118039465 (2011).
19. Krishnamoorthy, R., Trevino, L.A., Evans, R.M. Pharmaceutical latrunculin formulations. US20107785624 (2010).
20. DeCamp, J.B., Watson, P.S., She, J. Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones. US20087414137 (2008) & US20117947850 (2011).
21. Lampe, J.W., Watson, P.S., Slade, D.J. Bridged bicyclic Rho kinase inhibitor compounds, composition and use. US20110144150 (2011).
22. Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol 2011; 5:667-77.
23. Hagihara, M., Komori, K., Sunamoto, H., Nishida, H., Matsugi, T., Nakajima, T., Hatano, M., Kido, K., Hara, H. Indazole derivatives. US20097563906 (2009).
24. Hagihara, M., Komori, K., Sunamoto, H., Nishida, H., Matsugi, T., Nakajima, T., Hatano, M., Kido, K., Hara, H. Methods for treating a disease in which Rho kinase is involved. US20107855222 (2010) & US20110039891 (2011).
25. Nakajima, T., Matsugi, T., Hara, H. Therapeutic agent for glaucoma comprising Rho kinase inhibitor and prostaglandin. US20100063060 (2010) & US20120040994 (2012).
26. Nakajima, T., Matsugi, T., Hara, H. Methods for treating glaucoma. US20100041671 (2010).
27. Hatano, M., Nakajima, T., Matsugi, T., Hara, H. Therapeutic agent for glaucoma comprising Rho kinase inhibitor and ß- blocker. US20110263638 (2011).
28. Yamamoto T, Abe H, Kuwayama Y, Tanihara H, Araie M. Efficacy and safety of the Rho kinase inhibitor, K-115, over 24 hours in patients with primary open-angle glaucoma and ocular hypertension. Proceedings of 2011 Annual Meeting of the Association for Research in Vision and Opthalmology, Ft. Lauderdale, USA, 2011.
29. Tanihara H, Abe H, Kuwayama Y, Yamamoto T, Araie M. Ocular hypotensive dose-response efficacy and safety of the Rho kinase inhibitor, k-115, in patients with primary open-angle glaucoma and ocular hypertension. Proceedings of 2011 Annual Meeting of the Association for Research in Vision and Opthalmology, Ft. Lauderdale, USA, 2011.
30. Mizuno K, Isobe T, Koide T, Watanabe M, Kaneko Y, Inokuchi Y, et al. Ocular hypotensive mechanism of K-115, A Rho-kinase inhibitor, and Rho-kinase expression in the eye. Proceedings of 2011 Annual Meeting of the Association for Research in Vision and Opthalmology, Ft. Lauderdale, USA, 2011.
31. Mizuno, K., Matsumoto, J. Agent for prevention or treatment of glaucoma. US20090118299 (2009).
32. Mizuno, K., Matsumoto, J. Preventive or remedy for glaucoma. US20090082338 (2009).
33. Sugimoto, S., Mizuno, K., Takahashi, M., Kanebako, M. Preventing or treating agent for glaucoma. US20100233287 (2010).
34. Richards, L.A., Crean, C.S., Peterson, W.M., Trevino, L.A. Ophthalmic formulation of Rho kinase inhibitor compound. US20100022517 (2010).
35. Hellberg, M.R., Sharif, N.A., May, J.A., Rusinko, A., Chen, H.H. (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating Rho kinase-mediated diseases and conditions. US20070149548 (2007).
36. Hellberg, M.R., Sharif, N.A., May, J.A., Rusinko, A., Chen, H. H. (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure. US20107655662 (2010).
37. Chen, H.H., Rusinko, A., Hellberg, M.R., Severns, B.S., Henderson, A.J., Guo, C., Hadden, M. 6-Aminoimidazo [1,2- B]pyridazine analogs as Rho kinase inhibitors for the treatment of glaucoma and ocular hypertension. US2008079880 (2008).
38. Chen, H.H., Rusinko, A., Hellberg, M.R., Severns, B.S., Henderson, A.J., Guo, C., Hadden, M. 6-Aminoimidazo [1,2- b]pyridazine analogs as Rho kinase inhibitors for the treatment of Rho kinase-mediated diseases and conditions. US20107820670 (2010).
39. Chen, H.H., Sharif, N.A., Hellberg, M.R. Hydroxyamino- and amino-substituted pyridine analogs for treating Rho kinasemediated diseases and conditions. US20117867999 (2011).
40. Hellberg, M.R., Rusinko, A., Henderson, A.J., Guo, C., Hadden, M., Decornez, H.Y. Aminopyrazine analogs for treating glaucoma and other Rho kinase-mediated diseases and conditions. US20080269249 (2008) & US20100216777 (2010).
41. Chatterton, J.E., Clark, A.F. RNAi-mediated inhibition of Rho kinase for treatment of ocular disorders. US20070149473 (2007).
42. Kengatharan M, Wirostko BM, Umeno H, Hsu HH. Pharmaceutical profile of a novel Rho kinase (ROCK) inhibitor ATS907 for reduction of IOP in glaucoma. Proceedings of 2011 Annual Meeting of the Association for Research in Vision and Opthalmology, Ft. Lauderdale, USA, 2011.
43. Borchardt, A.J., Gardiner, E.M., Noble, S.A. Siegel, D.L. Novel inhibitors of Rho kinase. US2009031848 (2009).
44. Feng, Y., LoGrasso, P., Bannister, T., Schroeter, T., Fang, X., Chen, Y., Yin, Y., Smolinski, M.P., Wang, B., Sessions, H. Anilides and analogs as Rho kinase inhibitors. US20110038835 (2011).
45. Feng, Y., LoGrasso, P., Bannister, T., Schroeter, T., Sessions, H., Yao, L., Wang, B., Smolinski, M.P., Chen, Y.T., Yin, Y., Frackowiak- Wojtasek, B., Chowdhury, S. Benzimidazoles and analogs as Rho kinase inhibitors. US20110052562 (2011).
46. Feng, Y., LoGrasso, P., Bannister, T., Schroeter, T., Chen, Y.T., Yin, Y., Smolinski, M.P., Wang, B., Sessions, H. Benzopyrans and analogs as Rho kinase inhibitors. US20110150833 (2011).
47. Plettenburg, O., Lorenz, K., Weston, J., Loehn, M., Kleemann, H.W., Duclos, O., Jeannot, F. Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors. US20110190341 (2011).
48. Koki, M., Atsushi, I., Akifumi, O., Koh, K., Rintaro, Y., Minoru, S. Sulfonamide compound. US20117964613 (2011).
49. Arnold, L.D., Chen, X., Dong, H., Garton, A., Mulvihll, M.J., Smith, C.P., Thomas, G.H., Krulle, T.M., Wang, J. Fused heterobicyclic kinase inhibitors. WO2007001439 (2007).